Global Healthcare Opportunities, or GHO Capital Partners LLP, has announced the acquisition of Genesis Research, a provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services.
Founded in 2009 and headquartered in Hoboken, New Jersey, Genesis is a pioneer in RWE and HEOR services via tech-enabled data and science-first solutions, servicing market-leading innovators across the Life Sciences industry. Genesis optimizes drug development and evidences the clinical and commercial value of products via expert analysis, synthesis, communication and utilization of integrated Real-World Data (RWD). Genesis has an established footprint in the U.S. and U.K. with more than 120 employees.
With estimated double-digit growth year over year, and regulatory demands accelerating the volume and accessibility of RWD, Genesis Research’s purpose-built technology platforms integrate human and artificial intelligence to increase efficiency and improve performance to meet expanding market needs. The company’s data-agnostic approach to accessing and analyzing RWE enables utilization of the best data sources available which includes data drawn from a wide range of sources outside of clinical studies.
Genesis has announced that David Miller will be appointed as the new Chairman of the Board and will formally assume the role in 2022.
The Partners at GHO Capital, said, “The investment in Genesis follows years of work internally to identify market-leading platforms with ambitious management teams in RWE and HEOR. Recognizing the rapid growth and macro tailwinds driving the sector, we are delighted to back a leader in this space. With our investment and specialist expertise, we look forward to supporting the shared ambition for Genesis to become a global leader in RWE and HEOR.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!